PASITHEA THERAPEUTICS CORP. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
PASITHEA THERAPEUTICS CORP. (KTTA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $75.20 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2025-03-24
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-12-31 was $54.54K.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-09-30 was $50.16K.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-06-30 was $24.39K, a 65.21% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-03-31 was -$53.89K.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was $75.20K.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was -$2.30M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | $54.54K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $104.69K derived: sum of 2 quarters · filed 2025-03-24 | $129.09K derived: sum of 3 quarters · filed 2025-03-24 | $75.20K 10-K · filed 2025-03-24 |
| 2023-09-30 | $50.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $74.55K derived: sum of 2 quarters · filed 2024-11-13 | $20.66K 10-Q · filed 2024-11-13 | -$2.32M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $24.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$29.50K 10-Q · filed 2024-08-13 | -$2.37M derived: sum of 3 quarters · filed 2024-08-13 | -$2.40M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$53.89K 10-Q · filed 2024-05-14 | -$2.40M derived: sum of 2 quarters · filed 2024-05-14 | -$2.42M derived: sum of 3 quarters · filed 2024-05-14 | -$2.35M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$2.37M derived: sum of 2 quarters · filed 2024-03-29 | -$2.30M derived: sum of 3 quarters · filed 2024-03-29 | -$2.30M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$25.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $44.15K derived: sum of 2 quarters · filed 2023-11-13 | $42.20K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $70.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $68.17K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$1.95K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |